vs

Side-by-side financial comparison of BALCHEM CORP (BCPC) and MYRIAD GENETICS INC (MYGN). Click either name above to swap in a different company.

BALCHEM CORP is the larger business by last-quarter revenue ($270.7M vs $209.8M, roughly 1.3× MYRIAD GENETICS INC). On growth, BALCHEM CORP posted the faster year-over-year revenue change (8.1% vs -0.4%). Over the past eight quarters, BALCHEM CORP's revenue compounded faster (7.5% CAGR vs 1.9%).

Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

BCPC vs MYGN — Head-to-Head

Bigger by revenue
BCPC
BCPC
1.3× larger
BCPC
$270.7M
$209.8M
MYGN
Growing faster (revenue YoY)
BCPC
BCPC
+8.4% gap
BCPC
8.1%
-0.4%
MYGN
Faster 2-yr revenue CAGR
BCPC
BCPC
Annualised
BCPC
7.5%
1.9%
MYGN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BCPC
BCPC
MYGN
MYGN
Revenue
$270.7M
$209.8M
Net Profit
$40.3M
Gross Margin
70.0%
Operating Margin
20.5%
-2.7%
Net Margin
14.9%
Revenue YoY
8.1%
-0.4%
Net Profit YoY
8.7%
EPS (diluted)
$1.25
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCPC
BCPC
MYGN
MYGN
Q1 26
$270.7M
Q4 25
$263.6M
$209.8M
Q3 25
$267.6M
$205.7M
Q2 25
$255.5M
$213.1M
Q1 25
$250.5M
$195.9M
Q4 24
$240.0M
$210.6M
Q3 24
$239.9M
$213.3M
Q2 24
$234.1M
$211.5M
Net Profit
BCPC
BCPC
MYGN
MYGN
Q1 26
$40.3M
Q4 25
$39.2M
Q3 25
$40.3M
$-27.4M
Q2 25
$38.3M
$-330.5M
Q1 25
$37.1M
$-100.0K
Q4 24
$33.6M
Q3 24
$33.8M
$-22.1M
Q2 24
$32.1M
$-36.7M
Gross Margin
BCPC
BCPC
MYGN
MYGN
Q1 26
Q4 25
35.6%
70.0%
Q3 25
35.7%
69.9%
Q2 25
36.4%
71.2%
Q1 25
35.2%
68.5%
Q4 24
36.0%
71.7%
Q3 24
35.6%
70.2%
Q2 24
35.5%
69.6%
Operating Margin
BCPC
BCPC
MYGN
MYGN
Q1 26
20.5%
Q4 25
19.8%
-2.7%
Q3 25
20.4%
-11.3%
Q2 25
20.1%
-154.5%
Q1 25
20.4%
-14.8%
Q4 24
19.8%
-18.6%
Q3 24
20.0%
-9.4%
Q2 24
19.6%
-17.3%
Net Margin
BCPC
BCPC
MYGN
MYGN
Q1 26
14.9%
Q4 25
14.9%
Q3 25
15.1%
-13.3%
Q2 25
15.0%
-155.1%
Q1 25
14.8%
-0.1%
Q4 24
14.0%
Q3 24
14.1%
-10.4%
Q2 24
13.7%
-17.4%
EPS (diluted)
BCPC
BCPC
MYGN
MYGN
Q1 26
$1.25
Q4 25
$1.21
$-0.09
Q3 25
$1.24
$-0.29
Q2 25
$1.17
$-3.57
Q1 25
$1.13
$0.00
Q4 24
$1.03
$-0.47
Q3 24
$1.03
$-0.24
Q2 24
$0.98
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCPC
BCPC
MYGN
MYGN
Cash + ST InvestmentsLiquidity on hand
$72.9M
$149.6M
Total DebtLower is stronger
$119.9M
Stockholders' EquityBook value
$1.3B
$368.0M
Total Assets
$1.7B
$706.6M
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCPC
BCPC
MYGN
MYGN
Q1 26
$72.9M
Q4 25
$74.6M
$149.6M
Q3 25
$65.1M
$145.4M
Q2 25
$65.4M
$74.4M
Q1 25
$49.9M
$91.8M
Q4 24
$49.5M
$102.4M
Q3 24
$73.7M
$99.9M
Q2 24
$63.7M
$97.3M
Total Debt
BCPC
BCPC
MYGN
MYGN
Q1 26
Q4 25
$119.9M
Q3 25
$119.5M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
BCPC
BCPC
MYGN
MYGN
Q1 26
$1.3B
Q4 25
$1.3B
$368.0M
Q3 25
$1.3B
$372.8M
Q2 25
$1.3B
$388.1M
Q1 25
$1.2B
$704.9M
Q4 24
$1.1B
$701.1M
Q3 24
$1.2B
$731.7M
Q2 24
$1.1B
$740.5M
Total Assets
BCPC
BCPC
MYGN
MYGN
Q1 26
$1.7B
Q4 25
$1.7B
$706.6M
Q3 25
$1.7B
$728.1M
Q2 25
$1.7B
$677.3M
Q1 25
$1.6B
$1.0B
Q4 24
$1.6B
$1.0B
Q3 24
$1.6B
$1.1B
Q2 24
$1.6B
$1.1B
Debt / Equity
BCPC
BCPC
MYGN
MYGN
Q1 26
Q4 25
0.33×
Q3 25
0.32×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCPC
BCPC
MYGN
MYGN
Operating Cash FlowLast quarter
$40.1M
$10.6M
Free Cash FlowOCF − Capex
$33.8M
FCF MarginFCF / Revenue
12.5%
Capex IntensityCapex / Revenue
2.3%
Cash ConversionOCF / Net Profit
0.99×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCPC
BCPC
MYGN
MYGN
Q1 26
$40.1M
Q4 25
$67.3M
$10.6M
Q3 25
$65.6M
$21.1M
Q2 25
$47.3M
$-13.6M
Q1 25
$36.5M
$-16.3M
Q4 24
$52.3M
$6.6M
Q3 24
$51.3M
$700.0K
Q2 24
$45.0M
$2.6M
Free Cash Flow
BCPC
BCPC
MYGN
MYGN
Q1 26
$33.8M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
FCF Margin
BCPC
BCPC
MYGN
MYGN
Q1 26
12.5%
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Capex Intensity
BCPC
BCPC
MYGN
MYGN
Q1 26
2.3%
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Cash Conversion
BCPC
BCPC
MYGN
MYGN
Q1 26
0.99×
Q4 25
1.72×
Q3 25
1.63×
Q2 25
1.23×
Q1 25
0.98×
Q4 24
1.56×
Q3 24
1.52×
Q2 24
1.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons